MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-14-2025
Biomerica Interest Expense 2011-2026 | BMRA
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Biomerica
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 367 | 9 | 47 | 37 | 282 | 167 | 2.26 K | 142 | 302 | 1.58 K | 5.83 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.83 K | 9 | 1 K |
Quarterly Interest Expense Biomerica
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 256 | - | 10 | - | 5 | 5 | 47 | 5 | - | - | 47 | 47 | 47 | 37 | 280 | 37 | 100 | 180 | 124 | 180 | 69 | 18 | 36 | 18 | 36 | - | 18 | 17 | 18 | - | -302 | - | -6 | 1.13 K | 308 | 308 | 308 | 370 | 573 | 370 | 573 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 K | -302 | 155 |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 23.0 | 2.86 % | $ 248 M |  China |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.6 | -0.22 % | $ 2.03 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
106 K | $ 6.1 | 1.16 % | $ 179 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 39.93 | -1.67 % | $ 1.11 B | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 234.99 | -0.25 % | $ 172 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 12.98 | 6.97 % | $ 368 M | Israel |
 |
DexCom
DXCM
|
20.3 M | $ 68.47 | -2.33 % | $ 26.4 B | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 17.5 | -7.41 % | $ 941 M | USA |
 |
Celcuity
CELC
|
2.11 M | $ 105.54 | -3.33 % | $ 4.16 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 3.4 | 3.66 % | $ 108 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 101.77 | 0.14 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 27.9 | -0.39 % | $ 844 M | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 107.75 | -1.98 % | $ 13.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | $ 48.19 | 1.71 % | $ 10.7 B |  Niderland |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 146.41 | -2.48 % | $ 23.3 B | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 214.0 | -1.51 % | $ 11 B | USA |
 |
IQVIA Holdings
IQV
|
670 M | $ 243.4 | -0.36 % | $ 44.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 177.06 | -0.64 % | $ 19.7 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 5.77 | -3.27 % | $ 748 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 254.76 | 0.43 % | $ 21.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 189.39 | -6.67 % | $ 15.6 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 708.9 | -0.79 % | $ 58.5 B | USA |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 68.27 | -1.59 % | $ 4.72 B | USA |
 |
Agilent Technologies
A
|
81 M | $ 145.56 | -1.51 % | $ 44.3 B | USA |
 |
Bioventus
BVS
|
1.29 M | $ 8.0 | 5.12 % | $ 501 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 29.47 | 1.25 % | $ 20 B | Niderland |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
-1 K | $ 23.85 | 2.49 % | $ 31 M | USA |
 |
Mettler-Toledo International
MTD
|
74.6 M | $ 1 461.94 | -0.56 % | $ 31 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
1.1 M | $ 6.63 | -0.08 % | $ 601 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 4.64 | 1.75 % | $ 2.49 M | USA |